Bbjs Financial Advisors LLC boosted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 51,806 shares of the exchange traded fund’s stock after acquiring an additional 930 shares during the period. SPDR S&P Biotech ETF accounts for about 1.8% of Bbjs Financial Advisors LLC’s holdings, making the stock its 16th biggest position. Bbjs Financial Advisors LLC owned about 0.07% of SPDR S&P Biotech ETF worth $4,803,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC purchased a new position in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $396,844,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of SPDR S&P Biotech ETF by 30.3% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,136,000 shares of the exchange traded fund’s stock valued at $297,575,000 after buying an additional 730,000 shares during the last quarter. Jane Street Group LLC lifted its position in shares of SPDR S&P Biotech ETF by 68.7% during the 1st quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock valued at $91,197,000 after buying an additional 391,333 shares during the last quarter. Baymount Management LP bought a new position in shares of SPDR S&P Biotech ETF during the 1st quarter worth $34,160,000. Finally, Blackstone Inc. increased its holdings in SPDR S&P Biotech ETF by 674.8% in the 4th quarter. Blackstone Inc. now owns 337,030 shares of the exchange traded fund’s stock worth $30,093,000 after acquiring an additional 293,530 shares during the last quarter.
SPDR S&P Biotech ETF Stock Up 1.2 %
SPDR S&P Biotech ETF stock traded up $1.14 during midday trading on Tuesday, reaching $96.95. The stock had a trading volume of 7,068,169 shares, compared to its average volume of 10,276,531. The firm has a market capitalization of $7.39 billion, a PE ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 12 month low of $63.80 and a 12 month high of $103.52. The firm’s 50-day moving average price is $94.90 and its 200 day moving average price is $92.58.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- The Risks of Owning Bonds
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Following Congress Stock Trades
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.